The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
EFFECTOR THERAPEUTICS INC | COM | 28202V108 | 5,594,133 | 6,822,114 | SH | SOLE | 6,822,114 | 0 | 0 | ||
DESIGN THERAPEUTICS INC | COM | 25056L103 | 41,116,799 | 6,526,476 | SH | SOLE | 6,526,476 | 0 | 0 | ||
ARCELLX INC | COMMON STOCK | 03940C100 | 124,792,441 | 3,946,630 | SH | SOLE | 3,946,630 | 0 | 0 | ||
NKARTA INC | COM | 65487U108 | 2,919,999 | 1,333,333 | SH | SOLE | 1,333,333 | 0 | 0 | ||
ARS PHARMACEUTICALS INC | COM | 82835W108 | 26,886,450 | 4,012,903 | SH | SOLE | 4,012,903 | 0 | 0 | ||
MINERALYS THERAPEUTICS INC | COM | 603170101 | 30,597,930 | 1,794,600 | SH | SOLE | 1,794,600 | 0 | 0 |